Skip to content
    CMPS
    Earnings call· Jun 2026(Q2 FY26)

    COMPASS Pathways Q2 FY26 earnings call CMPS

    Aug 5, 2026 Source

    Executive summary

    COMPASS Pathways Q2 FY26 — COMP360 Phase III Data De-risks Clinical Profile, NDA Filing on Track for Q4

    COMPASS Pathways reported a strong second quarter, highlighted by highly statistically significant Phase III data for COMP360, which has largely de-risked its clinical and regulatory profile for Treatment-Resistant Depression. The company is on track to complete its NDA filing in Q4 FY26, with commercial preparations well underway for an anticipated H1 2027 launch. While regulatory and reimbursement timelines remain fluid, management expressed confidence in the blockbuster potential of COMP360 and its ability to fundamentally change mental health care.

    Highlights

    5

    • Highly statistically significant positive Phase III primary endpoint readout for COMP360, demonstrating rapid onset and durability through 6 months.

    • Strong balance sheet with $433 million cash on hand as of June 30, carrying through launch and into 2028.

    • NDA filing for COMP360 in TRD on track for Q4 FY26, with rolling submission already under FDA review.

    • Commercial readiness advancing, including hiring experienced leadership team and initiating sales force recruitment, with launch anticipated H1 2027.

    • Prescriber market research shows approximately 90% of interventional psychiatrists would prescribe COMP360 within the first year of availability.

    Concerns

    3

    • Launch timeline remains fluid due to the need for DEA and state rescheduling following potential FDA approval.

    • FDA guidelines on psychedelics, specifically regarding 12-month blinded durability, present a 'tall order' for future endeavors, though not expected to impact current regulatory process.

    • Reimbursement challenges are anticipated at launch, requiring ongoing engagement with payers and deployment of a field reimbursement team.

    Guidance & targets

    3
    CategoryTargetConfidence
    NDA Filing Completion
    Q4
    high materiality
    High
    COMP360 Launch Timing
    First half of 2027
    high materiality
    Medium
    Cash Runway
    Into 2028
    medium materiality
    High

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    COMP360 (Treatment-Resistant Depression)
    COMP360 demonstrated extremely rapid onset of action, deep and clinically meaningful reduction in depressive symptoms as quickly as 1 day, unprecedented durability sustained through at least 6 months, and reproducibility of effect in a chronic treatment-resistant patient population.
    Willingness to prescribe (interventional psychiatrists): ~90% within first year of availabilityTRD patient population: 4 million patients todayBlockbuster opportunity: Confident
    		————

    Operational metrics

    8
    Cash and Investments Balance
    $433M
    Q2 FY26

    Strong balance sheet, carries through launch and into 2028.

    Interventional Psychiatry Treatment Centers
    8,000+growing rapidly (adding ~500 per quarter)
    Current

    These sites are designed to support in-office treatments for products requiring multi-hour monitoring, such as Spravato, TMS, and ECT, and have existing capacity and staff.

    Commercial Leadership Team Product Launches Experience
    70+
    Cumulative

    The commercial leadership team members come from companies like J&J, Gilead, Okko, and Axon.

    Strategic Collaborations
    8
    Current

    These collaborations help inform priorities for optimal site and patient experience at launch.

    Willingness to Prescribe (Interventional Psychiatrists)
    ~90%highest ever seen in pre-launch market research
    Pre-launch market research

    This high percentage is attributed to the unmet need in the TRD patient population and the potential of COMP360.

    TRD Patient Population
    4M
    Current

    These patients have limited treatment options today, highlighting the blockbuster opportunity for COMP360.

    Administration Sessions in Silence
    80%
    Clinical trials (2b and PTSD)

    This data validates that the psilocybin experience is largely internal and supports a broader range of possibilities for who could monitor the patient.

    IIS Trained on Psychedelic Portion
    1,000+
    Current

    Part of third-party training grants, preparing for REMS requirements.

    Deals & partnerships

    2
    RadialStrategic collaboration to inform launch priorities

    One of 8 strategic collaborations, playing a critical role in helping to inform priority focus at launch of ensuring optimal site and patient experience.

    OsmindStrategic collaboration to inform launch priorities

    One of 8 strategic collaborations, playing a critical role in helping to inform priority focus at launch of ensuring optimal site and patient experience.

    Risks & headwinds

    3
    Fluid Launch Timeline due to Regulatory ReschedulingNear-term (H1 2027)

    Launch anticipated in H1 2027, but timeline remains fluid.

    Mitigation: Accelerating 8-factor analysis for FDA's Division of Controlled Substances, engaging with DEA, leveraging time between FDA approval and DEA rescheduling for site preparation.

    Reimbursement Challenges at LaunchInitial launch period (H1 2027)

    Traditional launches face initial reimbursement hurdles.

    Mitigation: Market access team engaging with payers, positive feedback from payers on TRD unmet need, deploying field reimbursement team at launch to assist sites with coding and reimbursement.

    FDA Guidelines on Psychedelics (Future Studies)Future clinical development

    12-month blinded durability requirement described as a 'tall order'.

    Mitigation: Current COMP360 regulatory process not expected to be impacted; future endeavors will carefully consider guidelines.

    What to watch in Q3 FY26

    4

    NDA Filing Completion for COMP360

    Q4 FY26
    CurrentRolling submission underway, some modules under FDA review
    TargetCompletion of NDA filing

    Why it matters

    Successful and timely completion of the NDA filing is crucial for regulatory approval and subsequent launch of COMP360.

    We continue to expect to complete the NDA filing in the fourth quarter.

    Q&A highlights

    6

    How do the new FDA guidelines, particularly the 12-month blinded durability requirement, affect COMP360's regulatory path and interpretation?

    Management believes the guidelines will not impact COMP360's current regulatory approval process, as their Phase III design was aligned with the FDA prior to the draft guidelines. They acknowledge the 12-month blinded durability is a 'tall order' for future studies but note the guidelines' support for complementary Phase III designs.

    “while the guidance is certainly interesting and we do have those on the 12 months blinded and that would seem like a pretty tall order in any psychiatry drug. We actually don't think it's going to impact the process of our regulatory approval at this stage.”

    asked by Paul Matteis · answered by Kabir Nath

    2 min read5 chapters

    Detailed Narrative

    01

    COMP360 Clinical Data & Regulatory Progress

    COMPASS Pathways announced highly statistically significant positive Phase III primary endpoint readout for COMP360 in Treatment-Resistant Depression (TRD), demonstrating rapid onset and durability through 6 months. These data reinforce the belief that COMP360 has the potential to fundamentally change mental health treatment. The company is making significant progress towards its NDA filing, with a rolling submission process underway and FDA already reviewing some modules. Completion of the NDA filing is expected in Q4 FY26, with a focus on a robust dossier for first-pass approval.

    02

    Commercial Readiness & Launch Strategy

    Commercial readiness initiatives are advancing, including the hiring of a highly experienced commercial leadership team and the initiation of sales force recruitment. The company has established 8 strategic collaborations, including with Radial and Osmind, to inform launch priorities. Launch is anticipated in H1 2027, leveraging the existing interventional psychiatry treatment center infrastructure (over 8,000 sites in the U.S.) which is already equipped to support multi-hour treatments. Market research indicates approximately 90% willingness to prescribe among interventional psychiatrists.

    03

    DEA Rescheduling & Reimbursement Outlook

    The launch timeline remains fluid due to the need for federal DEA and state rescheduling of psilocybin. The company is accelerating its 8-factor analysis for the FDA's Division of Controlled Substances and engaging with the DEA to clarify timelines, expecting rescheduling within 90 days of the DEA's review. On reimbursement, the market access team is engaging with payers, receiving positive feedback due to the high unmet need in TRD. A field reimbursement team will be deployed at launch to assist sites with coding and securing reimbursement.

    04

    FDA Guidelines on Psychedelics

    Management addressed the recently issued FDA guidelines on psychedelics, noting that while interesting, they are not expected to impact the ongoing regulatory process for COMP360. The company's Phase III design was aligned with the agency prior to the draft guidelines. Concerns were raised about the 'tall order' of 12-month blinded durability requirements mentioned in the guidelines for future studies, but the design of complementary Phase III studies remains consistent with COMPASS's approach.

    05

    Future Pipeline & Indications

    While the immediate focus is on the TRD launch, COMPASS Pathways is pursuing a Phase II study for COMP360 in PTSD, which is currently underway with 300 patients across three arms, including VA sites. The company is also restarting its Investigator-Initiated Study (IIS) programs, which had been paused, to explore other potential indications such as OCD. Real-world evidence collection is also planned to understand patient populations and future viable indications.

    AI-generated summary of the company’s earnings call. Not investment advice.